{"id":954643,"date":"2026-04-24T16:08:51","date_gmt":"2026-04-24T20:08:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/"},"modified":"2026-04-24T16:08:51","modified_gmt":"2026-04-24T20:08:51","slug":"intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/","title":{"rendered":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <em>World\u2019s first Phase 3 readout for an\u00a0<\/em>in vivo<em> CRISPR gene editing candidate<\/em><\/li>\n<li>\n          <em>Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026<\/em>\n        <\/li>\n<\/ul>\n<p>CAMBRIDGE, Mass., April  24, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u24h52NYtUqxqremanXrb7Fh3jKFRa8NS4zrfJsoQ4jxX9xYC1GW05CpivK9oxkNhdokc6HxMGyje0H2GOYDcz-OtKRvPWWn0vyrCaUwmns=\" rel=\"nofollow\" target=\"_blank\">Intellia Therapeutics, Inc.<\/a> (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data.<\/p>\n<p>To join the webcast, please visit the Events page of the Investors &amp; Media section on Intellia\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3XgIlBASPoK8ookNm4wJofDmqF0XAk_zLNyNMvAxyekYxzyFdRO7ZOFu-3tEMkwE8e3miFVTRJIzWszmk890quZOVkXV-wDXsaIvJrvgRhM=\" rel=\"nofollow\" target=\"_blank\">intelliatx.com<\/a>. A replay of the webcast will be available for approximately 90 days.<\/p>\n<p>\n        <strong>About Intellia Therapeutics<br \/><\/strong>Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company\u2019s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3XgIlBASPoK8ookNm4wJoWN6pbyTulu7_WYsBc3UylIc6EOFz6WEKIvsuQToGMZw6TkzBitD5MtiTsB0Jwiz_qt8lcE2sqFrQtJEmHUQCsc=\" rel=\"nofollow\" target=\"_blank\">intelliatx.com<\/a> and follow us <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iiuUJAox044M90DRXnVhqZA47k1Nd6DbChWsgWio_5jAsxsvd1eCuFd1GMfsfhrRnPH-815OeRwb5tepFcA38Q==\" rel=\"nofollow\" target=\"_blank\">@intelliatx<\/a>.<\/p>\n<p>\n        <strong><br \/>\n          <em>Investor Contact:<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Jason Fredette<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Intellia Therapeutics, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=20He1-NFdNfX0bdem64PoVeddsI0QIBmuS5YPWQ4vkeglqwDfLLQXUeCv4kV0QV-IcnDEY6lAdpYcESjT2ZKCQ0BKHcilzRkfOwOeTLG0amm6GgFb4L3Uv7OgG2anJJD\" rel=\"nofollow\" target=\"_blank\"><u>jason.fredette@intelliatx.com<\/u><\/a><\/p>\n<p>\n        <strong><br \/>\n          <em>Media\u00a0Contact:<\/em><br \/>\n        <\/strong><br \/>\n        <br \/>Mike Tattory<br \/>Vice President<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fpD-WExiXvmJPUxbHV2MpgAHM4wCau0VuNS4amxKhOc3x2mZYj5wiF-7aOWc5nnvL7ViZpJ3tuloteq_RJOm_kgdGvgSY7_DLXbedmflnvHsFb1I-wsZLSHtUa8oBu2Y7zPAbovysw9AKR_ADNz_YA==\" rel=\"nofollow\" target=\"_blank\"><u>mtattory@lifescicommunications.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGI5Y2YzYWItMzIyOS00NzkxLTg2MjItZDJkNzlmYWUwYWRlLTEwNDA3NzItMjAyNi0wNC0yNC1lbg==\/tiny\/Intellia-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>World\u2019s first Phase 3 readout for an\u00a0in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Investors &amp; Media section on Intellia\u2019s website at intelliatx.com. A &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-954643","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"World\u2019s first Phase 3 readout for an\u00a0in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Investors &amp; Media section on Intellia\u2019s website at intelliatx.com. A &hellip; Continue reading &quot;Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-24T20:08:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026\",\"datePublished\":\"2026-04-24T20:08:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/\"},\"wordCount\":251,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/\",\"name\":\"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\",\"datePublished\":\"2026-04-24T20:08:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/","og_locale":"en_US","og_type":"article","og_title":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk","og_description":"World\u2019s first Phase 3 readout for an\u00a0in vivo CRISPR gene editing candidate Company to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) &#8212; Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE) on Monday, April 27, 2026 and will host a webcast at 8:00 a.m. ET to discuss the data. To join the webcast, please visit the Events page of the Investors &amp; Media section on Intellia\u2019s website at intelliatx.com. A &hellip; Continue reading \"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-04-24T20:08:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026","datePublished":"2026-04-24T20:08:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/"},"wordCount":251,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/","name":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=","datePublished":"2026-04-24T20:08:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTY5Njc5NCM3NTU0OTI0IzIwMjkyMDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=954643"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/954643\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=954643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=954643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=954643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}